Skip to main content
S&P 5007,759.41-0.54%DOW51,129.61-0.10%NASDAQ27,194.18-1.25%BTC$80,581.00-3.21%ETH$2,413.00-5.58%GOLD$4,153.20+0.30%OIL$92.14+4.37%
Smart Investors Daily
SID Premium
CV

NASDAQ · CV

CapsoVision, Inc.

Healthcare · Medical - Equipment & Services

$6.54

Up+$0.16 (+2.38%)

Updated Oct 8, 2026, 6:24 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
674.03M
P/E ratio
-28.7
Dividend yield
0.00%
52-week range
$4.74 – $9.17
Volume
104.53K
Avg. volume
80.82K

Price performance · CV

CV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

CV closed at $6.54 after 21 trading sessions, up 2.67% for the selected period.

Last close
$6.54
Period change
+2.67%
Period low
$5.99
Period high
$6.92
Daily close
View OHLC price history
CV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$6.39$6.58$6.385$6.54104.53K
Oct 6, 2026$6.60$6.60$6.35$6.5069.48K
Oct 5, 2026$6.13$6.61$6.11$6.58590.37K
Oct 2, 2026$6.35$6.40$6.12$6.17128.72K
Oct 1, 2026$6.40$6.54$6.25$6.32159.43K
Sep 30, 2026$6.72$6.7862$6.37$6.46155.31K
Sep 29, 2026$6.90$6.98$6.55$6.69244.96K
Sep 28, 2026$6.60$6.94$6.50$6.92352.95K
Sep 25, 2026$6.18$6.69$6.17$6.65184.6K
Sep 24, 2026$6.05$6.19$5.88$6.17216.9K
Sep 23, 2026$6.26$6.32$6.03$6.05443.2K
Sep 22, 2026$6.25$6.33$6.00$6.30271.84K
Sep 21, 2026$6.91$6.91$6.07$6.19170.8K
Sep 18, 2026$6.26$6.75$6.26$6.701.61M
Sep 17, 2026$6.04$6.42$6.01$6.33174.71K
Sep 16, 2026$6.40$6.64$5.98$5.99508.98K
Sep 15, 2026$6.50$6.74$6.35$6.38250.55K
Sep 14, 2026$6.60$6.85$6.50$6.51224.55K
Sep 11, 2026$6.54$6.895$6.505$6.60207.06K
Sep 10, 2026$6.29$6.70$6.29$6.52163.62K
Sep 9, 2026$6.30$6.68$6.24$6.37185.25K

Latest CV news

The latest Smart Investors Daily articles mentioning CV.

Stock researchCompany · Overview

CV research

Overview

Company profile and research snapshot.

Company profile

CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
CV recent ratings
DateFirmRatingTarget
Mar 27, 2026BenchmarkSpeculative Buy—
Dec 31, 2025BenchmarkSpeculative Buy—
Jul 28, 2025BenchmarkSpeculative Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® systemSARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that AI Highlights™, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Fo

Yahoo · Sep 3, 2026

CapsoVision to Participate in Upcoming Investor Conferences

SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conf

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By